首頁 > 市場調查報告書 > 製藥

疫苗癌症

市場調查報告書

商品編碼

1557334

全球癌症疫苗市場 - 2024年至2029年預測

Global Cancer Vaccines Market - Forecasts from 2024 to 2029

出版日期: 2024年08月27日 | 出版商:

Knowledge Sourcing Intelligence | 英文 135 Pages | 商品交期: 最快1-2個工作天內

價格

簡介目錄

全球癌症疫苗市場預計將從2024年的101.96億美元增加至2029年的175.17億美元，預測期內年複合成長率為11.43%。

癌症疫苗用於治療或預防癌症，分為預防性癌症疫苗和治療性癌症疫苗。癌症疫苗是一種免疫療法，可以幫助摧毀癌細胞、阻止腫瘤生長並防止未來癌症在體內發展。

由於不健康的生活習慣，全球癌症患者數量不斷增加，是支持癌症疫苗市場成長的主要原因之一。越來越多的遺傳性癌症研究和該領域的結論性結果預計將推動癌症疫苗市場的顯著成長。 FDA 已核准針對人類乳突病毒 (HPV) 和乙型肝炎 (HBV) 的癌症疫苗，並可能在未來幾年推動市場的顯著成長。

眾所周知，癌症疫苗會對身體造成嚴重的後遺症，這可能會抑制癌症疫苗市場的成長。越來越多的基於天然植物的阿育吠陀療法用於癌症治療的研究預計將為未來的市場成長帶來一些障礙。老年人口中與老齡化相關的免疫力下降也可能威脅市場成長，因為它增加了疫苗接種後免疫反應減弱的可能性。此外，與癌症疫苗相關的高價格也可能阻礙市場成長。

全球癌症疫苗市場促進因素：

全球癌症患者數量的增加正在推動市場成長。

生活方式的改變、菸草和香菸等不健康產品的消費增加以及接觸輻射和病毒正在增加全世界癌症患者的數量。根據世界衛生組織（WHO）預計，2022年將通報近2,000萬新發癌症病例，死亡人數將達970萬人。

肺癌是癌症死亡的主要原因，佔新病例的 12.4%，其次是乳癌（11.6%）和大腸癌（9.6%）。到2050年，癌症新發病例數預計將達到5,500萬例，比2022年增加77%。由於癌症死亡率不斷上升，癌症疫苗的開發引起了高度關注。

遺傳性癌症症候群的增加：

有些癌症似乎是家族遺傳，可能是由增加癌症風險的相同暴露引起的，例如吸煙或遺傳性肥胖。然而，在某些情況下，例如遺傳性癌症，異常基因會代代相傳，導致癌症。據美國癌症協會稱，所有癌症中約 5% 至 10% 是直接由突變引起的。預計該領域的更多研究和結論性成果將為未來幾年癌症疫苗開發帶來成長前景。

全球癌症疫苗市場的地域展望

北美地區預計將大幅成長。

按地區分類，全球癌症疫苗市場分為北美、南美、歐洲、中東和非洲以及亞太地區。由於對癌症研究的持續投資和加強治療過程的努力，預計北美將佔據重要的市場佔有率。

主要經濟體，即美國，處於醫療創新的前沿，且癌症發生率正在顯著成長。根據美國癌症協會預測，2023年美國新增癌症病例和死亡人數預計將分別達到1,950萬人和609萬人。

限制全球癌症疫苗市場的因素：

免疫力較弱的老年人數量不斷增加將阻礙市場成長。

癌症疫苗市場的主要限制因素之一是免疫力下降的老年人口不斷增加。免疫力下降會抑制人體的免疫反應，進而降低癌症疫苗在體內有效反應的機會。根據聯合國資料，到2050年，全世界大約六分之一的人將超過65歲。

與癌症疫苗相關的副作用可能會限制市場擴張。

癌症治療疫苗可能會引起多種副作用，這取決於多種因素，包括癌症類型、分期、疫苗治療類型和劑量。美國國家癌症研究所列出了疲勞、頭痛、呼吸困難、虛弱、發冷、發燒、低血壓或高血壓以及某些過敏反應等副作用。 Cyprecel-T 可導致人類中風。對此類副作用及其嚴重的恐懼可能會阻礙癌症疫苗市場的成長。

其他治療方案的可用性可能會對市場成長產生負面影響。

阿育吠陀和自然療法在癌症治療中的可用性可能會威脅癌症疫苗市場的成長。儘管沒有嚴格的證據或核准明阿育吠陀作為一種醫學系統可以治療癌症，但研究人員發現瑜伽、冥想和阿育吠陀方法可作為癌症治療的補充療法。

此外，美國國家醫學圖書館下屬的國家生物技術研究中心編制了一份具有抗癌特性科學證據的特定植物清單，例如 Flacourtia Romanica、辣木、Ficus bengalensis 和 Semecarpus Anacardium。

全球癌症疫苗主要市場開拓：

2024 年 5 月，英國國民醫療服務體系 (NHS England) 宣布，作為「癌症疫苗啟動平台」的一部分，進行了首次針對治療腸癌的個人化疫苗的患者試驗。目的是讓希望參加臨床試驗的癌症患者能夠快速轉運到最近的參與醫院。
2023 年 7 月，英國政府與 BioNtech SE 達成協議，到 2030 年為約 10,000 名癌症患者提供該生物技術公司正在開發的最新治療方法和臨床試驗，包括疫苗試驗。該協議確保患者能夠從改進的治療方法中受益。
2022年12月，Moderna Inc.和默克公司將與默克公司的「KEYTRUDA」一起進行個人化mRNA癌症疫苗「mRNA-4157/V940」的2期試驗，以治療III/IV期黑色素瘤患者。治療。

全球癌症疫苗市場區隔分析如下：

依技術

樹突狀細胞 (DC) 癌症疫苗
重組癌症疫苗
抗原/佐劑癌症疫苗
全細胞癌症疫苗
病毒載體和 DNA 癌症疫苗
其他

按類型

癌症預防疫苗
治療性癌症疫苗

按用途

子宮頸癌
攝護腺癌
其他

按用途

兒科的
成人

按地區

北美洲
美國
加拿大
墨西哥
南美洲
巴西
阿根廷
其他
歐洲
英國
德國
法國
其他
中東/非洲
UAE
南非
以色列
沙烏地阿拉伯
其他
亞太地區
中國
日本
印度
澳洲
台灣
韓國
其他

The increased cases of cancer globally due to unhealthy living practices is one of the prime causes behind the cancer vaccine market's growth. The increasing research on inherited cancer and a definitive result in the field is expected to hold a large market for the growth of cancer vaccines. Cancer vaccines have been approved for Human papillomavirus (HPV) and Hepatitis B (HBV) by the FDA, which can provide significant growth to the market in the coming years.

Cancer vaccines are known for causing severe after-symptoms in the body, which may constrain the cancer vaccine market's growth. The increasing research for natural, plant-based Ayurveda therapy for cancer treatment is expected to create some hurdles for future market growth. The loss of immunity with age in the elderly population can also threaten the market's growth due to increased chances of low immune response after the vaccination. Besides that, the high price associated with cancer vaccines can also hamper their market growth.

Global Cancer Vaccine Market Drivers:

Increasing cases of cancer worldwide have propelled the market growth.

The change in lifestyle habits, followed by the increasing consumption of unhealthy products like tobacco and cigarettes and exposure to radiation and viruses, has been increasing the number of cancer patients worldwide. According to the World Health Organization , in 2022, nearly 20 million new cancer cases were reported, with an estimated number of deaths reaching up to 9.7 million.

Hence, the same sources further stated that lung cancer was the major cause of cancer deaths and accounted for 12.4% of new cases, followed by breast cancer at 11.6% and colorectal cancer at 9.6%. By 2050, the number of new cancer cases is estimated to reach 55 million, thereby witnessing a 77% increase over 2022's figure. The increasing rate of cancer mortality has put a major focus on the development of cancer vaccines.

Growing history of family cancer syndromes:

Certain types of cancer seem to run in families, which can be due to the same exposure that increases cancer risk like smoking and family running obesity. However, in some cases, like inherited cancer, an abnormal gene is passed along from one generation to another, which can lead to cancer. According to the American Cancer Society, around 5%-10% of all cancers result directly from mutations. Increasing research and a definitive result in this field are expected to hold growth prospects for developing cancer vaccines in the upcoming years.

Global Cancer Vaccine Market Geographical Outlook

North America is expected to grow significantly.

Regional-wise, the global cancer vaccine market is divided into North America, South America, Europe, the Middle East and Africa, and Asia Pacific. North America is expected to account for a considerable market share owing to the ongoing investment in cancer research and efforts to bolster the treatment process.

Major economies, namely the USA, are at the forefront of medical innovations and are witnessing significant growth in cancer prevalence. According to the American Cancer Society, in 2023, the expected number of new cancer prevalence in the USA reached 19.5 million, with the number of deaths reaching up to 6.09 million.

Global Cancer Vaccine Market Restraints:

Increasing elderly population with low immunity will hamper the market growth.

One of the major restraints on the cancer vaccine market is the growing elderly population, which is accompanied by low-immunity in people. This is expected to serve as a constraint for the market's growth as a weak immune system hampers the immune response of the body and thus reduces the chances of an effective response by the cancer vaccines in the body. UN data suggests that by 2050, around 1 in 6 people in the world will be over the age of 65.

The side effects associated with cancer vaccines can restrain the market expansion.

Cancer Treatment Vaccines can cause various side effects, which depend on various factors like the type of cancer, how advanced it is, the type of vaccine treatment, the dosage, etc. The National Cancer Institute has listed side effects like fatigue, headache, trouble breathing, weakness, chills, fever, low and high blood pressure, and certain allergic reactions. Sipuleucel-T can trigger strokes in human bodies. Fear of such side effects and their severity may hamper the cancer vaccine market's growth.

The availability of other treatment options can negatively impact the market growth.

The availability of Ayurveda and natural therapies in cancer treatment could threaten the cancer vaccine market growth. Although there is no strict evidence or approval that Ayurveda as a system of medicine can treat cancer, researchers have found that yoga, meditation, and Ayurveda approaches are helpful as complementary therapies in cancer treatment.

Besides that, the National Center for Biotechnology Institution, which is part of the U.S. National Library of Medicine, has compiled a list of certain plants, such as Flacourtia romantic, Moringa oleifera, Ficus bengalensis, Semecarpus Anacardium, etc., that have scientific evidence of anticancer properties.

Global Cancer Vaccine Key Market Development:

In May 2024, NHS England announced the first patient trial with a personalized vaccine for treating bowel cancer, which formed part of its "Cancer Vaccine Launch Pad". This aimed to enable cancer patients willing to participate in clinical trials to be fast-tracked to the nearest participating hospital.
In July 2023, the UK government formed an agreement with BioNtech SE, which involved providing nearly 10,000 cancer patients with the latest therapies and clinical trials being developed by the biotech firms, including vaccine trials by 2030. The agreement would ensure that patients can benefit from more improved treatment options.
In December 2022, Moderna Inc. and Merck announced phase 2 of their "mRNA-4157/V940," a personalized mRNA cancer vaccine that would be tested along with Merck's "KEYTRUDA" to analyze the treatment of patients suffering from stage III/IV melanoma.

The Global Cancer Vaccine market is segmented and analyzed as follows:

By Technology

Dendritic Cells (DC) Cancer Vaccines
Recombinant Cancer Vaccines
Antigen/Adjuvant Cancer Vaccines
Whole-Cell Cancer Vaccines
Viral Vector & DNA Cancer Vaccines
Others

By Type

Preventive Cancer Vaccines
Therapeutic Cancer Vaccines

By Application

Cervical Cancer
Prostate Cancer
Others

By End-Use

Pediatric
Adults

By Geography

North America
United States
Canada
Mexico
South America
Brazil
Argentina
Others
Europe
UK
Germany
France
Others
Middle East and Africa
UAE
South Africa
Israel
Saudi Arabia
Others
Asia Pacific
China
Japan
India
Australia
Taiwan
South Korea
Others

1. INTRODUCTION

1.1. Market Overview
1.2. Market Definition
1.3. Scope of the Study
1.4. Market Segmentation
1.5. Currency
1.6. Assumptions
1.7. Base and Forecast Years Timeline
1.8. Key Benefits for the Stakeholder

2. RESEARCH METHODOLOGY

2.1. Research Design
2.2. Research Processes

3. EXECUTIVE SUMMARY

3.1. Key Findings

4. MARKET DYNAMICS

4.1. Market Drivers
4.2. Market Restraints
4.3. Porter's Five Forces Analysis
- 4.3.1. Bargaining Power of Suppliers
- 4.3.2. Bargaining Power of Buyers
- 4.3.3. Threat of New Entrants
- 4.3.4. Threat of Substitutes
- 4.3.5. Competitive Rivalry in the Industry
4.4. Industry Value Chain Analysis
4.5. Analyst View

5. GLOBAL CANCER VACCINES MARKET BY TECHNOLOGY

5.1. Introduction
5.2. Dendritic Cells (DC) Cancer Vaccines
5.3. Recombinant Cancer Vaccines
5.4. Antigen/Adjuvant Cancer Vaccines
5.5. Whole-Cell Cancer Vaccines
5.6. Viral Vector & DNA Cancer Vaccines
5.7. Others

6. GLOBAL CANCER VACCINES MARKET BY TYPE

6.1. Introduction
6.2. Preventive Cancer Vaccines
6.3. Therapeutic Cancer Vaccines

7. GLOBAL CANCER VACCINES MARKET BY APPLICATION

7.1. Introduction
7.2. Cervical Cancer
7.3. Prostate Cancer
7.4. Others

8. GLOBAL CANCER VACCINES MARKET BY END-USER

8.1. Introduction
8.2. Pediatrics
8.3. Adults

9. GLOBAL CANCER VACCINE MARKET BY GEOGRAPHY

9.1. Introduction
9.2. North America
- 9.2.1. United States
- 9.2.2. Canada
- 9.2.3. Mexico
9.3. South America
- 9.3.1. Brazil
- 9.3.2. Argentina
- 9.3.3. Others
9.4. Europe
- 9.4.1. UK
- 9.4.2. Germany
- 9.4.3. France
- 9.4.4. Others
9.5. Middle East and Africa
- 9.5.1. UAE
- 9.5.2. South Africa
- 9.5.3. Israel
- 9.5.4. Saudi Arabia
- 9.5.5. Others
9.6. Asia Pacific
- 9.6.1. China
- 9.6.2. Japan
- 9.6.3. India
- 9.6.4. Australia
- 9.6.5. Taiwan
- 9.6.6. South Korea
- 9.6.7. Others